Clal Insurance Enterprises Holdings Ltd decreased its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 29.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 484,500 shares of the exchange traded fund’s stock after selling 206,500 shares during the quarter. Clal Insurance Enterprises Holdings Ltd’s holdings in SPDR S&P Biotech ETF were worth $61,885,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in the business. Cassaday & Co Wealth Management LLC acquired a new stake in SPDR S&P Biotech ETF in the 1st quarter valued at $85,000. Balefire LLC boosted its stake in shares of SPDR S&P Biotech ETF by 1.3% during the 1st quarter. Balefire LLC now owns 13,637 shares of the exchange traded fund’s stock worth $1,742,000 after buying an additional 178 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of SPDR S&P Biotech ETF by 1.2% during the 1st quarter. Parallel Advisors LLC now owns 27,604 shares of the exchange traded fund’s stock worth $3,526,000 after buying an additional 317 shares during the last quarter. PeakShares LLC boosted its stake in shares of SPDR S&P Biotech ETF by 5.2% during the 1st quarter. PeakShares LLC now owns 1,684 shares of the exchange traded fund’s stock worth $215,000 after buying an additional 84 shares during the last quarter. Finally, Independent Financial Group LLC bought a new position in shares of SPDR S&P Biotech ETF in the 1st quarter valued at about $888,000.
SPDR S&P Biotech ETF Price Performance
Shares of NYSEARCA XBI opened at $154.50 on Wednesday. The business has a 50-day moving average of $143.17 and a 200-day moving average of $132.89. The stock has a market capitalization of $10.37 billion, a price-to-earnings ratio of 11.47 and a beta of 0.82. SPDR S&P Biotech ETF has a fifty-two week low of $84.39 and a fifty-two week high of $165.71.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Recommended Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
